📊The DARE-AF trial published in
@CircAHA explored whether Dapagliflozin, an SGLT2 inhibitor, can reduce AF recurrence post-ablation in patients without typical indications for the drug.
Unlike earlier studies involving patients with conditions like heart failure or type 2 diabetes, this trial focused on 200 patients set for ablation without these comorbidities.
In our Journal Club video,
@ShelleyZieroth reviews the findings and their significance for SGLT2 inhibitors in new patient groups.
Watch to learn more about the study design and outcomes⤵️